The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Changes in Lung Function and Chylous Effusions in Patients With Lymphangioleiomyomatosis Treated With Sirolimus
Open accessAbstract
BACKGROUND: Lymphangioleiomyomatosis (LAM) is a disorder that affects women and is characterized by cystic lung destruction, chylous effusions, lymphangioleiomyomas, and angiomyolipomas. It is caused by proliferation of abnormal smooth muscle-like cells. Sirolimus is a mammalian target of rapamycin inhibitor that has been reported to decrease the size of neoplastic growths in animal models of tuberous sclerosis complex and to reduce the size of angiomyolipomas and stabilize lung function in humans. OBJECTIVE: To assess whether sirolimus therapy is associated with improvement in lung function and a decrease in the size of chylous effusions and lymphangioleiomyomas in patients with LAM. DESIGN: Observational study. SETTING: The National Institutes of Health Clinical Center. PATIENTS: 19 patients with rapidly progressing LAM or chylous effusions. INTERVENTION: Treatment with sirolimus. MEASUREMENTS: Lung function and the size of chylous effusions and lymphangioleiomyomas before and during sirolimus therapy. RESULTS: Over a mean of 2.5 years before beginning sirolimus therapy, the mean (±SE) FEV1 decreased by 2.8%±0.8% predicted and diffusing capacity of the lung for carbon monoxide (Dlco) decreased by 4.8%±0.9% predicted per year. In contrast, over a mean of 2.6 years of sirolimus therapy, the mean (±SE) FEV1 increased by 1.8%±0.5% predicted and Dlco increased by 0.8%±0.5% predicted per year (P<0.001). After beginning sirolimus therapy, 12 patients with chylous effusions and 11 patients with lymphangioleiomyomas experienced almost complete resolution of these conditions. In 2 of the 12 patients, sirolimus therapy enabled discontinuation of pleural fluid drainage. LIMITATIONS: This was an observational study. The resolution of effusions may have affected improvements in lung function. CONCLUSION: Sirolimus therapy is associated with improvement or stabilization of lung function and reduction in the size of chylous effusions and lymphangioleiomyomas in patients with LAM. PRIMARY FUNDING SOURCE: Intramural Research Program, National Heart, Lung, and Blood Institute, National Institutes of Health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Identification and characterization of the tuberous sclerosis gene on chromosome 16
(1993) · Cell · doi:10.1016/0092-8674(93)90618-z · Cited by 1,645
Efficacy and safety of sirolimus in lymphangioleiomyomatosis
McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M. L., Stocks, J. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100391 · Cited by 1,099
Self-citationTee, A. R., Fingar, D. C., Manning, B. D., Kwiatkowski, D. J., Cantley, L. C., & Blenis, J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202476899 · Cited by 827
Cited by
McCormack, F. X., Gupta, N., Finlay, G. R., Young, L. R., Taveira-DaSilva, A. M., Glasgow, C. G., Steagall, W. K., Johnson, S. R., Sahn, S. A., Ryu, J. H., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201607-1384st · Cited by 363
Self-citationLymphangioleiomyomatosis — a wolf in sheep’s clothing
Henske, E. P., & McCormack, F. X. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58709 · Cited by 307
The efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis
Ando, K., Kurihara, M., Kataoka, H., Ueyama, M., Togo, S., Sato, T., Doi, T., Iwakami, S.-I., Takahashi, K., Seyama, K., et al. (2013) · Respiratory Investigation · doi:10.1016/j.resinv.2013.03.002 · Cited by 106
Mayo clinic experience of lung transplantation in pulmonary lymphangioleiomyomatosis
Ussavarungsi, K., Hu, X., Scott, J. P., Erasmus, D. B., Mallea, J. M., Alvarez, F., Lee, A. S., Keller, C. A., Ryu, J. H., & Burger, C. D. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.08.014 · Cited by 26
Single lung transplantation for lymphangioleiomyomatosis: a single-center experience in Japan
Oishi, H., Watanabe, T., Matsuda, Y., Noda, M., Ejima, Y., Saiki, Y., Seyama, K., Kondo, T., & Okada, Y. (2018) · Surgery Today · doi:10.1007/s00595-018-1678-z · Cited by 17
Metadata
- Authors
- Taveira-DaSilva, A. M., Hathaway, O., Stylianou, M., & Moss, J.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2011-06-21
- Volume
- 154
- Issue
- 12
- Pages
- 797-805
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1968936684
- Cited by
- 203
- References
- 4
- FWCI
- 8.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Changes in Lung Function and Chylous Effusions in Patients With Lymphangioleiomyomatosis Treated With Sirolimus. https://app.cochat.ai/papers/10.7326/0003-4819-154-12-201106210-00007
- The paper
- Taveira-DaSilva, A. M., Hathaway, O., Stylianou, M., & Moss, J. (2011). Changes in Lung Function and Chylous Effusions in Patients With Lymphangioleiomyomatosis Treated With Sirolimus. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-154-12-201106210-00007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.